INTRODUCTION
The first stages of the study of eukaryotic gene expression revolved around the identification of positively acting transcription factors and the investigation of their function. It has since become clear that negative regulation of transcription is an equally vital process, in some way participating in the control of more or less all genes so far studied (for recent reviews, see [1] [2] [3] [4] ). Transcriptional repression is required for the establishment of the temporally and spatially complex patterns of gene expression which are characteristic of eukaryotes, and is also frequently involved in the modulation of gene expression in response to changes in the micro-environment of the cell. In this review we briefly discuss several mechanisms of negative regulation, before addressing the variety of cellular processes in which these mechanisms are involved.
MECHANISMS OF NEGATIVE REGULATION
The process of transcriptional regulation in eukaryotes is highly complex, allowing several stages at which negative regulatory events may intervene. For the purposes of discussion, some features of transcriptional regulation are illustrated schematically in Figure 1 .
The activation of transcription may be controlled by cytoplasmic retention of transcription factors. In the best studied example, members of the rel family of activators are retained in the cytoplasm by interactions with IKB factors. Dissociation of these interactions, and the subsequent migration of rel factors to the nucleus, is controlled by phosphorylation of the lKB factors ( [5] [6] [7] ; also see later). In the absence of its ligand the glucocorticoid receptor (GR) is also retained in the cytoplasm, through interaction with a complex which includes the 90 kDa heat shock protein hsp90 [8] . This should not be regarded as an exclusively negative regulatory event, since hsp9O may assist in the interaction of the glucocorticoid receptor with its ligand [9] .
In prokaryotes a common mechanism of negative regulation involves factors which bind near to or overlapping the site of binding of the polymerase complex, thus interfering with the formation of this complex ( Figure 1 , part 4; [10] ). Unlike their prokaryotic counterparts, eukaryotic promoters must often integrate responses to several afferent signals which regulate transcription both positively and negatively. This kind of integrated response is not possible if the promoter is unoccupied, perhaps explaining why such a 'promoter occlusion' mechanism is infrequently employed by eukaryotes. Apparent examples include the autoregulation of the simian virus 40 (SV40) early promoter by the T antigen, an early-gene product [l1] , and several instances of negative regulation by nuclear hormone receptors [12] [13] [14] [15] [16] .
A more commonly employed mechanism involves interference with the binding of transcriptional activators (binding competition; Figure 1 , part 5). A negatively acting factor binds to a sequence adjacent to or overlapping the binding site for an activator, and prevents the binding of the activator by steric hindrance [17] [18] [19] [20] [21] [22] [23] . This is an essentially passive mechanism characterized by dependence upon the relative positioning of positive and negative sites. The negatively acting factor is required only to bind DNA, and regions other than its DNA-binding domain are dispensible [24, 25] or replaceable [26] .
Transcription factors belonging to the same family may show similar or identical DNA-binding specficity, and thus may compete for binding sites when present in the same cell ( Figure 1 , part 9). This is true for instance of the Drosophila homeodomaincontaining proteins, which overlap extensively in specificity (see later). The cyclic AMP response element-binding factor (CREB) and the activator protein 1 (API) factors are related structurally and in DNA-binding specificity. CREB is able to recognize API consensus sites, but not to stimulate transcription in this context, and thus can down-modulate APl activity by competition for access to DNA [27] . The antagonism between CREB and APl at a non-consensus binding site has been shown to be modulated by cyclic AMP-dependent phosphorylation of CREB [28] .
As in the example above, the negatively acting displacement factor has often been previously described as a positive transcription factor, and it is then necessary to explain why the displacer does not activate transcription. A possibility deserving consideration is that the 'negative factor' may simply be the weaker of two activators which bind in a mutually exclusive fashion (see, for instance, ref. [29] ). An alternative theory has arisen from studies of negative glucocorticoid response elements U- 13 14 
Figure 1 Features of transcriptional activation and negative regulation
In this and in other figures, the convention is adopted that positively acting sites and factors are shown in red, and negatively acting sites and factors are shown in black. The multicomponent polymerase complex is assembled at the TATA box (TATA) or at the initiator element (InR) in promoters lacking a canonical TATA box. The complex has low 'basal' activity which is stimulated by transcription factors bound in cis (that is, on the same molecule of DNA). Activators may operate from near to the polymerase complex, or from great distances away. In the latter case, contact with the polymerase complex is thought to be permitted by looping out of the intervening DNA (part 1). Other features are described in the text.
(GREs). These diverge from the GRE consensus sequence, leading to the suggestion that receptor-DNA interactions at such sites differ from interactions at canonical sites, so that the receptor conformation is altered and productive interactions with the transcription machinery are prevented [30] [31] [32] . Some evidence in favour of this hypothesis comes from the observation of a highly unusual trimeric glucocorticoid receptor complex at a negative response element of the pro-opiomelanocortin promoter [33] . Dimers of the rel-related p50 transcription factor show different trans-activating properties at alternative binding sites [34, 35] , and such differences correlate with changes in sensitivity to a proteinase, suggesting alternative conformations at activatory and non-activatory sites [35] . Ligand [36] . The position of the dyad symmetry axis may influence the regulatory activity of the DNA-bound receptor dimer through effects upon its conformation. An oestrogen response element of the oxytocin promoter is similarly down-regulated by the retinoic acid receptor. A powerful activating domain can be fused to the retinoic acid receptor DNA-binding domain, generating a chimaera which binds strongly to the response element, but fails to activate transcription [37] . These observations challenge the view that simply tethering an activation domain to DNA is sufficient for stimulation of transcription, ;.nd suggest that sequence-directed features of the protein-DNA interaction may dictate regulatory properties. Attempts have also been made to relate differences in trans-activation to structural perturbations of the bound DNA, such as bending [38] . Bending of DNA has been ascribed to a growing number of transcription factors [39] [40] [41] ; however, the functional significance of this effect is presently unclear. Very many transcription factors bind to DNA as dimers ( Figure 1 , part 2), and possess specialized dimerization domains such as the 'leucine zipper' [42, 43] , the POU domain (named after the Pit-1, Oct and unc-86 proteins in which it was first mos-described; [44] ) and the helix-loop-helix motif [45] . There may be considerable (though not unlimited) dimerization promiscuity within a family of related proteins such as the activating transcription factor (ATF)/CREB, CCAAT/enhancer-binding protein (CEBP), T3R and APl families. For instance, the prototypical API factor is a heterodimer of c-Fos and c-Jun proteins which interact through leucine zipper motifs. There are at least four Fos-like and three Jun-like cellular proteins. Various heterodimeric combinations of Fos-type and Jun-type proteins are possible, in addition to homo-or hetero-dimers of Jun-type but not Fos-type proteins (reviewed in [46, 47] ). Such promiscuity is an enormous source of regulatory diversity, since different dimeric complexes may differ in DNA-binding and in transactivating properties [48,48a] .
Two types of negative regulatory interaction are observed. Firstly, a negatively acting factor may form a dimeric complex which fails to bind DNA, and thus represses transcription by sequestrating positive transcription factors in an inactive form ( Figure 1, part 6 ). The helix-loop-helix antagonists Id and extramacrochaetae (emc) [49] [50] [51] are able to dimerize with other helix-loop-helix factors (HLHs), but lack essential DNA-binding surfaces and down-regulate the activating potential of their dimerization partners (see later). Similarly, members of the POU domain and CEBP families attenuate the DNA-binding activity of their respective dimerization partners [52, 53] . Secondly, the negatively acting factor may form a dimeric complex which is able to bind DNA, but lacks domains required for transcriptional activation ( Figure 1, part 10 ). In this case the negative factor not only may compete for occupation of cis-acting regulatory sites, but may also function by sequestering activators in transcriptionally inert heterodimeric complexes. The protooncogene product c-myc requires dimerization with its partner max (myc auxilliary factor) in order to bind DNA efficiently, to activate transcription and to achieve its oncogenic effect ( [54, 55] , and references therein). Nevertheless, when in excess over myc, max is a negative regulator of transcription, forming homodimers which bind DNA but do not activate transcription [56, 57] . This illustrates the potential for large changes in transcriptional activity through small changes in the ratios of dimerization partners. Myc-dependent transcriptional activation is also negatively regulated by alternative max partners, mad [58] and mxil [59] , which form DNA-binding but non-activating complexes with max, thus competing for the essential cofactor of myc, and for occupancy of binding sites. Other examples of such behaviour have been described, including two members of the CREB family, CREM [60, 61] and CREB-2 [62] ; the CEBP-related factor LIP (liver-enriched inhibitory protein) [63] ; a basic HLH leucine zipper factor mTFE3 [64] ; and two members of the API family, JunB [66, 67] and FosB-S [68] [69] [70] .
Interestingly, several negatively acting factors are the products of genes which also encode transcriptional activators, and are generated through alternative splicing of primary transcripts [61, 64, [68] [69] [70] [71] , or through alternative use of translation initiation codons [63, 72] . The generation of positive and negative factors from the same transcript may be subject to developmental, tissue-specific or signal-responsive regulation, providing an additional level at which gene expression may be controlled [73] .
As well as interactions between structurally related proteins, there may be unexpected negative regulatory interactions between factors belonging to entirely different classes, for instance between c-Jun and the glucocorticoid receptor [74, 75] or between c-Jun and myogenic factor D (MyoD) [76] . It Figure 1, part 13 ; [77] ). Similarly, the mammalian retinoblastoma gene product Rb does not bind directly to DNA, but modulates the regulatory activity of DNA-binding factors with which it interacts ( Figure 1 , part 11; [78] ; see later). The c-myc gene is positively regulated by a binding site for the transcription factor CFl (common factor 1) [79] . An adjacent sequence negatively regulates c-myc transcription, and because binding of proteins to the two sites is co-operative it is suggested that the negative regulatory factor acts by masking activation domains of CFI ( Figure 1 , part 14; [80] ). Genes expressed specifically in yeast a-type cells are activated by a non-cellspecific factor GRM (general regulator of mating type). Cell specificity of GRM activity appears to be regulated by an a cellspecific factor which binds co-operatively with GRM at sites flanking the GRM binding site, and may down-modulate transcription by masking the activation surface(s) of the positive factor [81] and/or by recruiting a general negative regulatory factor to this site [82] .
There is strong evidence that transcription factors transmit their activating signals to the polymerase complex through the action of intermediary factors or cofactors ( Figure 1, part 3 ; [83] [84] [85] ). This is most clearly shown by the phenomenon of 'squelching', in which the presence of large excesses of transcription factors, or of their activation domains, interferes with transcription activation by sequestrating the putative cofactors [86] . Squelching events can be observed in vivo without artificially high concentrations of the negatively acting factor [87] ; thus the cofactors may be limiting for some transcription activation processes, and squelching may be a physiologically significant mechanism of regulating gene expression.
The adenovirus Ela gene products not only activate transcription of viral genes, but are also able to repress transactivation by a huge number of cellular transcription factors [88] [89] [90] [91] [92] [93] [94] [95] [96] [97] . Binding to DNA is required for neither positive nor negative regulatory activity. One possible explanation of the breadth of Ela action is that it interferes with the transmission of activating signals by interaction with cofactors ( Figure 1 , part 7) or with the polymerase complex ( Figure 1 , part 8; [94] ). An interaction of Ela with the TATA box-binding factor TFIID (transcription factor IID) has been demonstrated [98] , and this may mediate both positive and negative effects upon transcription.
The mechanisms described above are essentially passive, involving interference with stages of transcriptional activation. In contrast, 'silencing' is an active process which may be regarded as a mirror image of enhancer activity ( Figure 1, part 12) . In other words, it involves direct inhibition of transcription initiation, possibly by causing a disruption of the polymerase complex at the promoter, or by otherwise impairing the catalytic activity of the complex. The first described silencer element [99] showed classical enhancer-like properties of acting upon cis-linked promoters at great distance and independently of orientation. Other silencers have demonstrated varying degrees of dependence upon position and orientation [100] [101] [102] [103] [104] [105] . Several appear to resemble enhancers in that they are composite in structure [105] [106] [107] [108] [109] [110] [114] [115] [116] [117] [118] , raising the possibility that silencing may be as functionally diverse as transcriptional activation.
Silencing and other negative regulatory processes may involve effects upon chromatin structure (reviewed in [4, 119, 120] ). The most compelling evidence for this comes from studies in yeast. For instance, the archetypal yeast silencer, which switches off expression of the HMRa silent mating-type locus, contains a functional autonomous replication sequence [107, 121] . Some observations suggest a role for replication in the establishment of the transcriptionally inert state of the silent mating-type loci [122, 123] ; however, this remains controversial [124] . It is not known how replication may influence transcriptional regulation. The establishment of domains of chromatin structure is emerging as an important stage in transcriptional regulation [125, 126] , and may also be involved in silencer function. A factor binding to the silencers of the yeast mating-type genes is required for nuclear scaffold attachment and for transcriptional repression [127] . Negatively acting sites which flank the mouse immunoglobulin heavy chain enhancer overlap with potential scaffold attachment sites, suggesting that repression of enhancer activity may be mediated through effects on chromatin loop formation ([128] ; see later). In spite of these indications, the evidence for largescale chromatin structural effects in silencer activity remains weak, at least as far as higher eukaryotes are concerned.
DNA methylation may theoretically play a role in the effect of replication upon transcription. Hypermethylation is known to be associated with a state of transcriptional silence (reviewed in [129] ); however it has been difficult to establish a causal relationship (e.g. see [130] ). CpG methylation has been shown to repress transcription in vivo and in vitro, either by directly influencing binding of transcription factors [131] , or indirectly through the action of methyl-specific DNA-binding proteins which may block the access of transcription factors [132] [133] [134] [135] [153, 161, 168 ,169]), and it remains to be seen whether these will similarly be found to function indirectly.
In several instances the loss of tissue-specific gene expression in intertypic hybrids has been correlated with the disappearance of a trans-acting positive regulatory factor thought to be essential for efficient transcription (Table 1) . Frequently the loss of the trans-activator has been shown to occur at the level of tran- Table 1 The disappearance of tissue-specific transcription factors implicated in the extinction of certain genes Down-regulation of messenger RNA encoding the relevant transcription factor is indicated in the third column. Abbreviations: IEFI, insulin enhancer factor 1; TTF1, thyroglobulin transcription factor 1; LEF1, lymphoid enhancer-binding factor 1; ND, not determined. scription of the corresponding gene (see Table 1 ). These findings suggest that the transcriptional silence of tissue-specific genes in somatic cell hybrids is again a lack-of-activation phenomenon. However, it remains to be established that the loss of a tissuespecific activator causes extinction, rather than being a consequence of an extinction event occurring at some higher regulatory level. [185, 186] , zincfinger [187, 188] , rel-related [189] , or basic leucine zipper [190] classes. The demonstration and analysis of transcriptional regulatory properties in a variety of systems permits the gap to be closed between genetically defined positive or negative function and detailed descriptions of molecular mechanisms of action. A few selected examples from this large field of research will serve to illustrate some of the general principles. We concentrate upon early events of anterior-posterior pattern formation. Similar negative regulatory mechanisms are involved in the action of homeotic selectors such as Antennapaedia and Ultrabithorax (see e.g. [191] [192] [193] [194] [195] ), and in the dorsal-ventral pattern formation process (see e.g. [101, [196] [197] [198] [199] ).
In the developing blastoderm, the expression of the gap gene Kriippel is activated by the maternal morphogen bicoid [200] . Restriction of Kriippel expression to a broad central domain is dependent upon negative regulatory interactions with other gap genes giant, knirps and tail-less [190, [201] [202] [203] . In the Kriippel promoter, multiple binding sites for the activator bicoid overlap with tail-less, knirps or giant binding sites [190, 203] . A small fragment containing overlapping bicoid and knirps binding sites activates transcription in response to bicoid, and this activation is blocked dose-dependently by knirps, which alone does not influence transcription [203] . This suggests a model for the generation of the Kriippel pattern in which overlapping gradients of activators and repressors compete for access to overlapping binding sites. This is a powerful mechanism for sensing and interpreting morphogen gradients, and appears to be frequently employed during Drosophila embryogenesis.
At the next level of the regulatory hierarchy, each of the pairrule genes comes to be expressed in a series of seven narrow bands encircling the embryo. In the case of pair-rule genes such as even-skipped (eve) and hairy, individual domains of expression appear to be regulated by more or less distinct and independent cis-acting elements [204] [205] [206] [207] . The sharp boundaries of the second stripe of eve expression are dictated by competition between the activators bicoid and hunchback, and repressors giant and Kruippel within the eve stripe two regulatory element ([108,208-210] ; Figure 2 ).
It is suggested that repressors must act by passive, short-range mechanisms in order to permit the independent regulation of discrete stripe regulatory elements [208, 210] . For engrailed proteins, which alone do not influence transcription [24, 25, 217] . This is a passive, binding competition effect which reflects similarities in sequence specificity of the activators and negative regulators. The deletion of a transcription-activating Kr -) domain from z2 allows it to behave like eve and engrailed, blocking activation by competing with activators for access to DNA [25] . Although a silencer-like mode of action has also been described for eve [218] , this may be related to an unusual binding competition mechanism, involving co-operative interactions between eve at a high-affinity distal site and at a low-affinity Posterior _ promoter-proximal site, where its binding interferes with the binding of transcription activators [219] . Both positive and negative properties have been demonstrated for a number of Drosophila transcription factors [1 17,191,196] , underlining the context-dependence of regulatory activity. Bidirectional regulation may be dictated by variations in the -1000 sequences bound, or by different protein-protein interactions at different cis-acting elements [220, 221] , and clearly increases the regulatory repertoire possible with a finite number of transm m R acting factors. W -. of Kruppel appear more complex than predicted in this model, and direct silencer-like activity has been observed in cultured mammalian [115] and Drosophila [117] cells. In the latter study Kriippel also displayed concentration-dependent activation and repression of a synthetic promoter containing a single binding site, an effect seemingly dependent upon distinct regulatory properties of monomeric and dimeric Kriippel complexes [117a] . It is not yet clear how these complex properties of the Kruppel protein relate to its function in embryonic pattern formation.
The so-called secondary pair-rule gene fushi tarazu (ftz) is regulated somewhat differently from the eve and hairy genes. Rather than being activated within specific embryonic domains, it is activated in a broad region and specifically repressed within interstripe domains [211, 212] , at least in part through the action of other pair-rule genes such as hairy [213, 214] . The ftz promoter contains several positive and negative sites [211, 215] . Against a background of uniform expression driven by a non-cell-specific promoter, multiple copies of individual negative sites restore zebra striped expression [215] .
In the final stage of embryonic pattern formation, parasegmental compartments are established through the action of segment polarity genes (for a definition of the term 'compartment', see [182] ). Many of the regulatory proteins involved in the establishment of this pattern, and in subsequent developmental stages, contain a conserved DNA-binding structure known as the homeodomain. Conservation of the homeodomain results in substantial overlap of DNA-binding specificity, whilst greater divergence outside of the homeodomain may help to explain the very distinct regulatory properties ( [186] ; see also references in [216] ). In a number of experimental systems, activation of transcription by homeodomain factors such as zerknullt (zen) and zen-related (z2) can be blocked by eve or
Differentiation in vitro
Certain cell lines can be induced to undergo differentiation in vitro by treatment with appropriate agents, and thus constitute useful systems for investigating molecular events in differentiation. For example, the retinoic acid-induced differentiation of embryonal carcinoma cell lines models early events in embryogenesis [222] . The response to retinoic acid includes the transcriptional activation of several cellular genes, and a switch from non-permissive to permissive behaviour for viral replication ( [223, 224] ; reviewed in [225] ). Retinoic acid influences the programme of gene expression both directly, by activating transcription of target genes (e.g. [226] ), and indirectly, by altering expression of genes encoding transcription factors. For instance, the gene encoding the embryo-specific Oct3 factor is negatively regulated by retinoic acid [227] . Since Oct3 itself may negatively regulate some target promoters [228] , its disappearance might lead to transcriptional derepression. The c-jun gene is derepressed by retinoic acid [229] , and its product participates in differentiation-linked activation of several cellular genes [230] . Following the induction of differentiation the c-Jun-containing API complex also activates the polyomavirus enhancer, displacing a labile repressor, PEA2, from its DNA-binding site [231, 232] . Largely using the changes in viral regulation as an experimental system, other investigators have provided evidence for limiting amounts of labile negative regulators of transcription in the undifferentiated embryonic stem cell [233] [234] [235] . These putative repressors remain to be characterized.
The proliferating 3T3-L1 preadipocyte cell line can be induced to differentiate into mature adipocytes, and this is accompanied by the transcriptional activation of several adipocyte-specific genes (reviewed in [236] ). De-repression of the stearoyl-CoA desaturase 2 gene is accompanied by changes in protein binding within a region which shows silencer activity in preadipocyte and HeLa cells [237] . The activation ofthe 442(aP2) promoter appears to involve displacement of a negative regulatory complex by an API complex [23, [238] [239] [240] . Finally, several adipocyte-specific genes are activated by the transcription factor CEBPa [240] [241] [242] .
CEBPa is expressed in the course of terminal differentiation [242] [243] [244] , and the expression of a conditionally active form in transfected cells causes growth arrest [245] . Thus CEBPa may constitute part of a proliferation-differentiation switch. This type of switching behaviour is better understood in the context of myogenesis.
Myogenesis is governed by basic helix-loop-helix factors (bHLHs) typefied by MyoD, myogenin and MRF4 (muscle regulatory factor 4) (reviewed in [246] [247] [248] ). These muscle-specific proteins dimerize with the widely expressed bHLH products E12 and E47, and bind to cis-acting 'E boxes' (consensus sequence CANNTG, where N is any nucleotide) upstream of musclespecific genes. Dimerization is mediated by the helix-loop-helix domains, and DNA binding by the adjacent basic domains of both proteins. In CH310T! cells the myogenic differentiation process can be initiated by forced expression of some (but not all) muscle-specific HLH proteins. Myogenesis and cellular proliferation are mutually antagonistic, as indicated by a large number of observations (reviewed in [248a] ). On the one hand, the overexpression of MyoD inhibits proliferation, even in cells in which it fails to initiate the myogenesis programme [249, 250] . On the other, several agents including serum [251, 252] , protein kinases A and C [253, 254] , the phorbol ester 12-0-tetradecanoylphorbol 13-acetate (TPA) [255] , transforming growth factor /3 (TGF,) and fibroblast growth factor (FGF) [251, 254, 256, 257] , and the oncogenes ras [258, 259] , myc [260, 261] , fos and jun [76, 262] , interfere with the programme of muscle differentiation. Three mechanisms have been suggested for the inhibition of myogenesis: down-regulation of expression of myogenic regulators, interference with their DNA-binding activity, and interference with the transmission of their activating signal. Because myogenic factors auto-activate their own expression [263] , the first of these effects may follow indirectly from either of the others.
TGF,/ inhibits the trans-activation function of myogenin, MyoD, myfS (myogenic factor 5) and MRF4 [256, 257] , but does not interfere with DNA-binding activity, at least of myogenin [251] . TGF,/ exerts its negative effect through the bHLH region of myogenin, but shows no activity against the ubiquitous HLH protein E47 [256] . A muscle-specific cofactor has been suggested to contact the bHLH region of myogenic regulators [264] , and this may be a target of TGF,J action.
FGF interferes with the regulatory activity of myogenic HLH proteins by a mechanism involving protein kinase C [254] . Protein kinase C phosphorylates myogenin at a conserved threonine residue within the basic domain, and in vitro this modification interferes with DNA binding by myogenin-E12 heterodimers. Inhibition of phosphatase activities also inhibits myogenesis [265] , indicating that there may be a requirement for active dephosphorylation to initiate or maintain the regulatory activity of HLHs. Protein kinase A also interferes with myogenic HLH regulatory activity; however, this is not directly correlated with phosphorylation of the HLH proteins, and must involve an indirect mechanism [253] . Possible mediators of the effect of protein kinase A include c-Fos and c-Jun.
Activated ras oncoprotein interferes with the myogenesis programme [258] , and this activity is mimicked by overexpression of Fos or Jun proteins [76, 258, 262] . Conversely, the overexpression of MyoD blocks transcriptional activation by API at its cognate binding site [76] . Both phenomena are titratable, thus the ratio of AP1 components to myogenic factors is decisive, arguing against sequestration of an essential cofactor as the mechanism. The basic helix-loop-helix region of MyoD is a target of negative regulation by Jun, and again the ubiquitous HLH protein E47 is not affected [262] . An interaction between the leucine zipper of c-Jun and the helix-loop-helix region of MyoD has been demonstrated [76] . The [266, 267] , insulin [268, 269] and exocrine pancreas-specific [270] genes, among others (see [271] for a review of HLH proteins in differentiation). In [277, 279] . In several mammalian tissue culture systems for the study of differentiation, the induction of differentiation is accompanied by a transient or sustained decrease in mRNA encoding nHLH proteins, and the transient or sustained appearance of E box binding activity in nuclear extracts [76, 272, 275, 280] . The overexpression of Id in transfected cells inhibits the activity of immunoglobulin, insulin or muscle cellspecific enhancers, and is able to block the execution of certain differentiation programmes [273, [280] [281] [282] [283] .
It increase in the concentration of the activatory bHLHs. These events themselves are as yet poorly understood.
The immunoglobulin genes
The intronic enhancer of the immunoglobulin heavy chain gene contains numerous binding sites for tissue-specific as well as widely distributed transcription factors [284] . Maximal enhancer activity is observed in mature lymphoid B-cells where the gene has undergone somatic rearrangement. However, non-tissuespecific enhancer activity can be detected in some non-lymphoid tissues, whilst in others (liver, foetal fibroblasts) the enhancer is completely silent [285] . Negative regulation of immunoglobulin enhancers has been suggested by extinction in B-cell-non-B-cell somatic hybrids [154, 173, 174, 179, 181, 286] ; by repression of in vitro transcription of immunoglobulin genes when non-B-cell nuclear extracts are added to B-cell nuclear extracts [287] ; and by the cycloheximide induction of a transfected immunoglobulin gene in fibroblasts [288, 289] . Mutagenic studies have revealed distinct mechanisms of negative regulation. Firstly, the enhancer is flanked by negative regulatory elements which down-regulate its activity in non-Bcells and in immature B-cells, but have no effect in mature B-cells [128, 142] . Both of these elements are required for the negative effect, and their position flanking the enhancer is essential. Within the negative regulatory regions defined by mutagenesis, binding sites have been discovered fir d factor NF-,uNR which is most abundant in non-B and immature B-cells [128] . NF-,tNR forms tetrameric complexes, suggesting that direct interactions between molecules at separated, enhatji'er-flanking sites may lead to a structural alteration of the intervening DNA, impeding the action of enhancer-binding factors ([128a] ; Figure 3 ). Additionally, NF-,uNR sites overlap potential nuclear matrix attachment and topoisomerase II sites [290] , again hinting that its negative regulatory function may involve influences over local DNA structure. This mechanism may resemble the complete silencing of enhancer activity observed in some tissues, and may help to explain why factors present in numerous tissues footprint the enhancer only in the B lineage [266, 267] .
Other studies starting with smaller enhancer fragments have revealed further mechanisms of negative regulation. Non-tissuespecific activators are able to bind to the ,uE5 motif [291] and to the nearby ,uE3 motif [292] . It has been shown independently by Kadesch et al. [293] and by Weinberger et al. [294] that mutations or deletions within this region can increase enhancer activity in non-B-cells. In fact, a complex regulatory system exists to regulate the activity of ,uE3 and ,uE5 sites outside the B lineage ( [295] ; Figure 4 ). The ,uE3 site alone is able to stimulate transcription in non-B-cells, but this stimulation is blocked by an adjacent #E5 Active transcription is indicated by a horizontal arrow above the appropriate gene TF1 is an unexpressed pseudogene, and 8 is weakly expressed in the adult bone marrow. The LCR activates each of the genes in turn, and this requires the sequential inactivation of e and y genes at the correct developmental stages (indicated by horizontal bars below these genes).
motif. Negative regulation is presumably mediated by a transacting factor, since it can be overcome by the forced expression of the ,uE5 binding factor ITF-1. The overall activity of this region may be finely regulated by binding competition at the ,uE5 site between an activator which synergizes with TFE3 (transcription factor E3) and a repressor which blocks the activity of TFE3.
Finally, an element which mediates B-cell-specific activation of the human immunoglobulin heavy chain enhancer is a target of negative regulation in HeLa cells [296] . Also, as described above, octamer sites may not only activate transcription in B-cells, but also negatively regulate transcription in non-B-cells [173, 179, 181] . A strikingly common feature is the involvement of cis-acting sequences in both positive regulation within the B-cell lineage and negative regulation outside this lineage. Factors mediating such negative effects have so far proved difficult t4 identify, so that it remains unclear at what level of transcriptional regulation they operate.
The globin genes
The sequential expression of the genes in the a-like and 3-like globin gene clusters during ontogeny has served as a paradigm for the study of developmental regulation in higher eukaryotes (reviewed in [297, 298] ). In humans the fl-like genes are physically arranged and temporally expressed in the order e (expressed in the embryonic yolk sac), Gy and Ay (in the foetal liver), then 8 and , (in the adult bone marrow) (see Figure 5 ). This switching of expression is regulated at two levels. Firstly, the locus control region (LCR) upstream of the e gene exerts a dominant influence over the entire cluster, and is required for the efficient expression of each of the genes (see [297] and references therein). Secondly, stage-specific control elements influence the activity of individual promoters.
Correct developmental regulation of the human globin gene depends upon competition of cis-linked genes for the influence of the LCR. In the absence of other genes of the locus, the promoter is deregulated (active at abnormally early stages of development) in transgenic mice [299, 300] . In contrast, both human e and y promoters are correctly regulated in the absence of other genes [301] [302] [303] [304] [305] , and therefore must be specifically switched off by stage-specific control elements. A silencer element has recently been identified upstream of the e globin gene [100] . The deletion of this element partially deregulates e gene expression in transgenic mice, leading to low levels of transcription in the adult bone marrow [301] . Within the silencer region both ubiquitous and erythroid-specific factors bind [100, [306] [307] [308] [309] , the latter probably being GATA or a related protein [309] . This suggests a mechanism of developmental regulation of the silencer, namely that increasing concentrations of GATA lead to the displacement of silencer factor(s). It may also explain why the deletion of this region does not lead to high levels of gene expression in the adult bone marrow, GATA being a wellcharacterized powerful activator of transcription in erythroid cells.
Mechanisms of developmental switching of the human y globin genes are less clear. However, some clues may come from analysis of HPFH (hereditary persistence of foetal haemoglobin) syndromes, in which y globin genes fail to become inactivated (reviewed in [310] ). Several forms of HPFH entail large deletions 3' of the y globin genes, suggesting the existence of negative regulatory elements in this region [311, 312] . Other HPFH forms are associated with single base changes within the promoter sequences which have been shown to alter the binding of nuclear factors [313] [314] [315] [316] [323, 324] , growth factors [325] , extracellular calcium [326] and double-stranded RNA [327] . Some selected examples are described here, beginning with the steroid/thyroid family of hormones.
The nuclear hormone receptors The nuclear hormone receptors belong to a much-studied extended family of transcription factors with more than 70 members, and representatives in organisms as diverse as man and Drosophila (reviewed in [328] [329] [330] ). An important distinction is made between the GR-related subfamily and the T3R-related subfamily. [30] [31] [32] . A pro-opiomelanocortin promoter fragment containing a high-affinity GR-binding site activates a heterologous promoter and confers repressibility by the synthetic glucocorticoid dexamethasone [32, 334] . Internal deletions removing the negative GRE (nGRE) reduce the basal activity of the pro-opiomelanocortin promoter and prevent repression by dexamethasone [32, 335] . Deletions removing an upstream region which does not contain a GR-binding site also reduce basal expression and interfere with repression by dexamethasone [32, 335] . It may be that efficient transcription depends upon co-operative interactions between proximal and distal positive sites, and that a function of the GR is to disrupt this interaction. As discussed earlier, a novel protein-DNA complex at the pro-opiomelanocortin nGRE has been described [33] [26, [336] [337] [338] .
Some investigators have reported negative regulation by the ligand-free T3R at high-affinity binding sites [339] [340] [341] [342] . In the presence of the aporeceptor, T3R binding sites show silencerlike properties of relative position/orientation-independence, an ability to operate upon heterologous promoters, and additive effects with increased copy number [106, 341, 343 ]. An active silencer domain is found in the T3R, in the closely related oncogenic product v-ErbA and in the retinoic acid receptor [114,114a] . The silencing domain of the retinoic acid receptor acts only in some cell lines, apparently due to tissue-specific influences of an adjacent ligand-independent positive regulatory domain [114] . The v-ErbA product, a virally transduced thyroid hormone receptor protein, has lost its ability to bind ligand, and behaves as a constitutive negative regulator [341] . The [12] [13] [14] [15] [16] 346] . These sites are commonly very divergent from the binding consensus sequence. Effects of ligand upon the affinity of receptor for such sites might help to explain why they are not negatively regulated by the nuclear-localized ligand-free members of the T3R family. Certainly their sequences, rather than simply their positions, are of critical importance [347, 348] .
The T3, retinoic acid, retinoid and vitamin D receptors are related in structure and in DNA-binding specificity, with sites being constructed from (most often two) versions of the AGGTCA hexamer. The binding and regulatory activities of different receptors at an individual site are dependent upon the spacing and orientation of the hexamers, their precise sequence and possibly contextual sequences, complicating the task of constructing useful predictive rules for the specificity of hormonal action [331, [349] [350] [351] [352] . In any event a clear consequence of overlapping binding specificities and the nuclear localization of receptors is that one receptor may interfere with transcriptional activation by another, due to binding site competition [26, 37, 353] . The ability of ligand-free receptors to occupy binding sites may block the access of other members of the receptor superfamily, and contribute to the specificity of action of these sites in cells which co-express receptors [339, 340, 354] .
The ability of a cell to respond to different ligands may also be modulated by the presence of the COUP (Chicken Ovalbumin Upstream Promoter) factors. These orphan receptors are structurally related to the T3 family of receptors, recognize the same half-site sequence, and show flexibility in terms of the arrangement and spacing of pairs of half-sites which can be bound by dimers [355] . In co-transfection experiments COUP factors were shown to block the activation of transcription by ligand-bound vitamin D, T3 and retinoic acid receptors [355] [356] [357] [358] , presumably by competition for the respective response elements, although the formation of inactive heterodimers is also a possible mechanism. This negative activity of the COUP factors suggests an important role in the regulation of development and differentiation, through regulation of transcriptional responses to various hormones.
Finally, nuclear hormone receptors may activate transcription indirectly by alleviating repression [359, 360] . For instance, upstream oestrogen response elements of the Xenopus laevis vitellogenin B1 promoter co-operate with promoter-proximal elements to overcome the effect of an intervening negative regulatory element [361] . This co-operativity is potentiated by the precise positioning ofa nucleosome between the two positively acting regions [362] .
Cross-talk between regulatory pathways The metazoan cell must co-ordinate its response to a large number of afferent signals by activating or switching off distinct programmes of gene expression. A case in point is that proliferation and differentiation frequently require the expression of discrete sets of genes. Thus a signal which activates the proliferative pathway must as rapidly and effectively shut down expression of genes active in the quiescent, differentiated state.
Conversely, signals which induce differentiation must shut down the proliferative pathway. The ability to switch reversibly between expression programmes is dependent upon extensive cross-talk between signal transduction machineries, constituting a 'regulatory lattice' of interactions. Some of the elements of this lattice are becoming increasingly well understood, in particular those which involve the API family of transcriptional regulators (reviewed in [362] [363] [364] [365] [366] ).
The API factors are well-characterized, dimeric transcription factors which are commonly (but not exclusively) involved in proliferative processes [46, 47] . Activation of the protein kinase C pathway, for instance by the phorbol ester TPA, leads to the activation of transcription by API complexes, which bind at TPA response elements (TREs). In contrast to API, the steroid/thyroid hormones are commonly found to induce differentiation, or to maintain cells in a quiescent state. Antagonism between the proliferative function of AP1 factors and the differentiative function of the nuclear hormone receptor factors has been frequently noted, and a number of distinct mechanisms have been described (see Figure 6) .
Several laboratories have independently demonstrated that nuclear hormone receptors interfere with transcriptional activation by API complexes [74, 75, [367] [368] [369] . TREs linked to the thymidine kinase promoter render this heterologous promoter repressible by the nuclear receptors [75, [368] [369] [370] . DNA binding of the receptor is not required for its negative regulatory activity; however, the zinc-finger DNA-binding domain is necessary [74, 75] . Binding activity and repressor activity of the GR can be uncoupled, since a mutation in one of the DNA-binding zinc fingers retains binding but loses repressor activity [74] . Thus the DNA-binding domain must also be involved in protein-protein interactions which mediate its negative effect upon the API complex. C-terminal regions may also mediate repression, as deletions in this region show diminished (GR [75] ) or abolished (retinoic acid receptor and T3R [367, 370] ) repressor activity.
API components have also been shown to down-regulate the activity of nuclear hormone receptors [74, 75, [371] [372] [373] . The lqm leucine zipper of c-Jun is implicated in negative regulation of GR function [75] , whilst an N-terminal region of c-Fos is required for negative regulation of GR function. This N-terminal domain is absent from FosB, which fails to down-regulate GR function [374] . Interactions between receptors and API components have been demonstrated in vivo and in vitro [74, 371] , the simplest hypothesis being that such interactions mutually inhibit DNA binding of the two classes of proteins (Figure 6a ). Mutual inhibition of DNA binding is observed in vitro [74, 75, 367, 370, 372] ; however, it is not clear that this occurs in vivo [369] . By genomic footprinting it has been shown that a negative effect of GR upon transcription activation by the API complex is not accompanied by changes in the DNA-binding activity of the API complex [375] . Because fos is reportedly a preferential target of the negative activity of GR [376] , downregulation of API activity may be explained by a shift in API composition from c-Jun/c-Fos heterodimers to c-Jun homodimers, which are weaker activators of transcription. Alternatively, the activity of the API complex may be modulated through the formation of a tertiary complex of API, TRE and GR [369] (Figure 6b ), although firmer evidence for the existence of such a complex in vivo is required.
A third mechanism of cross-talk involves competition between an activator and a negative regulatory factor for access to overlapping DNA-binding sites, and differs from the mechanism described above in that DNA binding is absolutely required for negative regulatory function (Figure 6c ). Binding interference of this kind may be involved in the cross-talk of API with steroid hormone receptors at the osteocalcin promoter, where a retinoic acid response element overlaps an API binding site [377] , and at the a-fetoprotein promoter, where a GRE overlaps an APIbinding site [29, 30] .
A fourth cross-talk mechanism has been described [363, 364] , in which factors belonging to the API and nuclear hormone receptor families co-occupy a so-called 'composite response element' (Figure 6d) . A composite element of the proliferin gene confers GR-dependent stimulation where c-Jun homodimers occupy the API site, GR-dependent repression where c-Jun/ c-Fos heterodimers occupy the APl site, and confers no GR response in cells lacking APl activity [378, 379] . Thus the balance of AP1 components acts as a cell-specific selector of the magnitude and direction of hormone response, and this is determined by the basic domains of the API components [380] . Binding of GR to the proliferin composite response element has so far beeti demonstrated only with high concentrations of purified receptor [381] . Certain features of the action of GR at composite sites might be explained by selective interference with the DNA binding of different APl components [376] . It will thus be important to demonstrate the co-occupancy of composite sites by members of the two families of transcription factors, a central feature of this putative mechanism of cross-talk (cited in [363] ).
Finally, a novel mechanism has been shown for APl-receptor cross-talk in the negative regulation of the interleukin 2 promoter by the GR [382, 383] . Nuclear factor of activated T-cells (NFAT) and an AP1-related complex co-operate to activate transcription. Neither site alone is a target of negative regulation by the receptor; however, the juxtaposition of the two sites creates a GR-repressible cis-acting element. The receptor, which does not bind to this sequence, down-regulates transcription by disturbing the synergy of the two positive sites [383] .
An astonishing variety of both positive and negative cellspecific, factor-specific and promoter-specific interactions between nuclear hormone receptors and API factors have been demonstrated [372, 373, [384] [385] [386] [387] [388] [389] . Work is at a preliminary stage different interactions, on and off DNA. Distinct receptor interactions are demonstrated by different members of the Fos and Jun families [364, 374] , perhaps providing a framework for understanding the apparent functional redundancy encoded within these families.
The rel family of transcription factors The rel family of transcription factors includes the oncogene v-Rel, its cellular counterpart c-Rel, the Drosophila morphogen dorsal, and a nuclear factor binding to the immunoglobulin K enhancer B motif (NFKB) (reviewed in [390] [391] [392] [393] ). The latter, a heterodimer of 50 and 65 kDa subunits [394] , is involved in tissue-specific gene expression in mature B-lymphocytes, and also participates in transcriptional induction of some genes by external signals such as cytokines in non-lymphoid cells [395] . Various other homo-and hetero-dimeric complexes of rel-type proteins also bind to DNA, but differ in sequence specificity and in transcriptional regulatory activity [34, 35, [396] [397] [398] .
The regulatory activity of rel family members is governed by a unique machinery which involves the IKB factors. The interactions between rel and IKB proteins are comprehensively reviewed elsewhere [392] , and the reader is directed to this review for a more complete discussion and list of references.
Several IKB-type proteins have so far been identified, and shown to differ subtly in their properties ( ; other references in [392] ). All have in common a region of similarity to the structural protein ankyrin, which appears to mediate interactions with specific rel factors [408, 412] . With possible exceptions [401, 404] , these interactions result in cytoplasmic retention [5, 6, 409] , probably through masking of nuclear localization signals [400, 405, 409, 425] . A second aspect of negative regulation by lKB is inhibition of the DNA-binding and thus the trans-activating function of rel factors [394, 407, 413, [422] [423] [424] . The rel family proteins p50 and p52 are synthesized as larger precursors, the C-terminal regions of which contain ankyrin-like repeats, and demonstrate IKB activity (referred to as IKBy) [408, 409, 411, [415] [416] [417] 420] . The activation of p50 and p52 requires (as a first step) a proteolytic cleavage between the relrelated and IKB-related domains [403] . Free IKBy may also be generated through alternative processing of primary transcripts encoding the precursors of p50 and p52 [411, 415] . Cell surface signals lead to the dissociation of rel-IKB interactions, and the migration of the rel factors to the nucleus. This event is correlated with changes in the phosphorylation state of IKB [399, 413, 414, 419, 426] , and although it is not yet known how such changes are effected, it is clear that different IKB species are inactivated on different signal transduction pathways [413, 414, 426] . [413, 414, 426] , the well-documented differences in specificity of IKB species for targets within the rel family [410, 418, 422] , and the differential binding and activating properties of various homo-and hetero-meric rel complexes at alternative binding sites [34, 35, [396] [397] [398] (Figure 7 ). The PRDI motif is highly related to the interferon-stimulated response elements (ISREs) which mediate transcriptional responses of several other genes to interferons. It is now clear that these sequences are targets for binding of several complexes which differ in precise binding specificity, inducibility and distribution [437] [438] [439] [440] [441] [442] [443] [444] [445] [446] [447] . One complex, interferon-responsive factor 1 (IRFI), behaves as an activator of transcription [438, 446] , whilst others may oppose transcriptional activation by competing for the binding site of IRFI and/or other activators [439, 440, 442, 444, 447] . Negatively acting factors which are induced by stimulating treatments may contribute to the postinduction transcriptional repression of /JIFN and other genes.
Like the NFKB-rel system, the extremely elaborate interferon response system appears to rely upon a large family of related factors which act through similar sequences but differ in their regulatory properties and patterns of induction. Cell-to-cell differences in the expression of members of this family are thought to contribute to differences in the magnitude, duration and signal specificity of transcriptional responses [440, 444] . enhancer by NFKB is specifically blocked by a negative regulatory factor which binds in cis [427] . The Drosophila rel-related protein dorsal behaves as a repressor of zen gene expression, and this negative activity requires a co-repressor which binds adjacent to dorsal binding sites [220, 221] . Figure 7 ). De-repression of transcription by deletion of NRDI [429, 431] or by competition with NRDI sequences [432] suggests that a role of this region is to block constitutive transcriptional activation, and to maintain a state of poised repression. Although its overlap with PRDII suggests a binding interference mechanism, NRDI retains its negative activity when widely separated from the PRDII motif upon which it acts [431] . PRDII is a target for binding of rel-related factors, and is thus subject to the negative regulatory mechanisms discussed above. In stimulated cells PRDII synergizes with the adjacent PRDI motif to activate transcription [433] . Following the transient response, both PRDI and PRDII sites participate in a postinduction switch-off event which, unlike the rapid induction of transcription [433] , requires de novo protein synthesis [434] [435] [436] .
Transient responses: los and immediate-early genes
The c-fos promoter is rapidly and transiently increased in response to several proliferative signals (references in [46] ). Negative regulation is required for the repression of basal transcription, and for the post-induction shut-off which follows transient activation. Many regulatory processes involve the dyad symmetry element, which is 300 bp upstream of the transcription start site. The multifunctional nature of this cis-acting element is reflected by its complexity and by the large number of ubiquitous and tissue-specific factors by which it is recognized (reviewed in [448] ). At the centre of the region of symmetry is the serum response element (SRE), which belongs to the CArG [CC(A/T)6GG] class ofregulatory sites. The SRE is constitutively bound by the serum response factor p67SRF, or SRF [449, 450] , with other factors binding at the 5' and 3' boundaries of the SRF-SRE complex [451, 452] . Adjacent to the SRE is the socalled FAP (fos APl-binding sequence) site, which is able to bind API complexes, ATF and CREB [453] .
The FAP site is involved in the transcriptional response to protein kinase C [454] , and also negatively regulates transcription in unstimulated cells [455, 456] . This is revealed by the increase in basal expression caused by in vivo competition with FAP oligos [455] , by mutation of the FAP site,or by altering its spacing from the adjacent SRE [456] . FAP thus appears to co-operate with the SRE in both induction of transcription by some external signals and the maintenance of low unstimulated expression. An involvement of API complexes in the latter is implied by downregulation of basal promoter activity in the presence of transfected Fos or Jun, and up-regulation when antisense Fos or Jun mRNAs are expressed [455] .
The post-induction shut-off of serum-stimulated c-fos transcription is due to negative autoregulation, and constitutive Fos protein expression diminishes or inhibits the serum response of endogenous or transfected c-fos promoters [457, 458] . The negative autoregulatory capacity of Fos protein involves its Cterminal domain [459, 460] , and may be controlled through its phosphorylation state [460] . Importantly, negative regulation of the serum response does not require the ability of Fos protein to interact with Jun, or to activate transcription [461] , discounting the possibility of indirect repression by activation of expression of a negative regulatory factor.
The SRE alone is sufficient to act as a target of transrepression [458, [462] [463] [464] [465] , although in the intact c-jos promoter other sequences may also be involved in this process [457] . Other promoters including those of the Krox-20 and Krox-24 genes are transiently activated in response to serum refeeding. Like the c-fos promoter these contain CArG motifs which mediate transrepression by Fos, hinting at a common mechanism for the postinduction shut-off of several immediate-early genes [458] . In mobility shift assays Fos protein is not present in complexes formed by SRF at the SRE [465] , thus its mechanism of action is not known. It is not excluded that SRF and Fos may interact directly, this interaction being too weak or unstable for detection in mobility shift assays. Alternatively Fos may interact with a cofactor necessary for stimulation of transcription by SRF. Because some factors are able to recognize sequences overlapping the SRE, the possibility arises that negative regulation may occur by competition for DNA binding. A zinc-finger protein YY l competes for binding to the SRE in titro, and in cotransfection experiments attenuates the response of the c-fos promoter to serum ( [466] ; also see [467, 468] [470] ), and the disruption of such a feedback loop may play an important role in cellular transformation [471] . Transience of transcriptional responses may also be achieved through cross-regulatory interactions between immediate-early gene products; for instance, Fos and Jun have been described as negative regulators of the c-myc gene [472, 473] . The following section describes a further class of regulatory events involved in controlling the cellular response to proliferative signals.
CONTROL OF GENE EXPRESSION IN THE CELL CYCLE
The strict regulation of proliferation is of obvious central importance to eukaryotic cells, because of the potentially oncogenic consequences of unregulated growth. The mechanisms controlling proliferation are increasingly well understood, and revolve around tumour suppressor proteins such as p53 and the retinoblastoma susceptibility gene product (Rb) (reviewed in [474] [475] [476] [477] [478] [479] ). The p53 and Rb proteins act as 'gatekeepers' of the cell cycle, blocking progression through the cycle unless proliferative signals converge appropriately. Their negative regulatory role is suggested by the discovery of mutations of the corresponding genes in a wide variety of tumours (references in [474, 478] ). Cell lines lacking functional tumour suppressor proteins are cell-cycle deregulated, and normal regulation can be restored by the introduction of wild-type p53 or Rb (e.g. [480, 481] ). Finally, oncoproteins of tumour viruses specifically interact with the tumour suppressor proteins, these interactions being essential for the oncogenic process (references in [474, 477] ). It appears that growth suppression by both p53 and Rb is at least partly accounted for by negative regulation of transcription, as we will now describe.
The Rb protein interacts with several cellular proteins [482] , including Spl [483] [484] [485] , ATF2 [486] , c-myc [487] and the ets-like factor Elf-i [488] . Its best understood interaction is with the as a regulator of the adenovirus E2 gene [493] . Binding sites for E2F are found in the promoters of several cell-cycle-regulated genes, including those for cdc2, thymidine kinase, DNA polymerase a, c-myb, c-myc and dihydrofolate reductase ( [494] [495] [496] ; other references in [497] ). The developmentally regulated transcription factor DRTF1 [498, 499] is extremely similar to E2F, and is not discussed separately here. E2F forms multicomponent DNA-binding complexes which alter in composition through the cell cycle [500] , and contain Rb protein during the GI phase [501] . Rb is subject to cyclical phosphorylation [502] [503] [504] , and is hypophosphorylated in the GI phase when complexed with E2F [489] . Two distinct lines of evidence indicate that this G1-specific E2F-Rb interaction may mediate negative effects of the tumour suppressor upon cell growth. Firstly, Rb arrests the cell cycle in GI phase [480] . Secondly, tumour virus oncoproteins (SV40 T antigen, adenovirus Ela protein and human papillomavirus E7 protein) interact exclusively with hypophosphorylated Rb, suggesting that this is an important target of the oncogenic process [505, 506] . The oncoproteins share an ability to disrupt the interaction between E2F and Rb [507, 508] , and mutant oncoproteins which fail to disrupt this interaction fail to deregulate growth. In cotransfection experiments E2F behaves as a potent, binding-sitedependent transcriptional activator. Wild-type Rb inhibits transcriptional activation by E2F [509, 510] , and a phosphorylation-defective mutant is a particularly potent repressor [509] , in agreement with the proposed negative regulatory role of the hypophosphorylated form. Rb not only interferes with transcriptional activation by E2F, but may convert the E2F complex into a transcriptional repressor [78] . This [511, 512] . An undoubtedly oversimplified model for the role of Rb in cell-cycle control is illustrated in Figure 8 . In the quiescent cell Rb is present in E2F complexes, downregulating expression of target genes which are required for progression through the cell cycle. Proliferative signals lead to the phosphorylation of Rb, the dissociation of the E2F-Rb interaction, and the release of E2F as a transcriptional activator. This normal cell-cycle regulation is mimicked by two potentially oncogenic events: infection with tumour viruses, the oncoproteins of which sequester Rb, or mutations of Rb which prevent the interaction with E2F.
Unlike Rb, p53 possesses sequence-specific DNA-binding activity in its own right [513, 514] and in several systems displays properties of a binding site-dependent transcription activator [515] [516] [517] [518] . It also exerts negative regulatory control over many cellular and viral promoters [519] [520] [521] [522] [523] [524] . The identification of cisacting targets of negative regulation by p53 has proved difficult. In fact, minimal promoters containing little more than a TATA box can be down-regulated [522, 525] , repression possibly being mediated by direct interactions of p53 with the TATA-binding factors [525] [526] [527] . Several The Wilms tumour suppressor gene product WTI plays an important role in regulating proliferation in the developing kidney [528] . It is a zinc-finger DNA-binding protein which recognizes the same sites as the mitogen-inducible transcription activator Krox24 [529] [530] [531] . In transient transfection assays it represses transcription from the insulin-like growth factor II and platelet-derived growth factor A chain genes [532] [533] [534] , both of which encode potent mitogens. The DNA-binding domain of WTI is not sufficient for full repression, which therefore does not simply depend upon binding site competition between WTI and Krox24 [118, 533] . The N-terminus of WTI contains a glutamineand proline-rich active repressor domain, which can convert Krox24 into a repressor in domain swapping experiments [118] .
The three tumour suppressor proteins discussed above share an ability to negatively regulate transcription, but otherwise differ in their properties. WT1 behaves as a tissue-specific silencerlike factor, regulating expression of growth factor genes in the kidney. p53 may be a broad-specificity negative regulator of transcription, and is also thought to control proliferation through regulation of DNA replication (references in [474] 
